Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

Modern Rheumatology

Volumn 25, Issue 6, 2015, Pages 817-824

  Takeuchi, Tsutomu ^a   Yamanaka, Hisashi ^b   Tanaka, Yoshiya ^c   Sakurai, Takeo ^d   Saito, Kazuyoshi ^c   Ohtsubo, Hideo ^e   Lee, Sang Joon ^f   Nambu, Yoshihiro ^g  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d Inoue Hospital   (Japan)

^e Kagoshima Red Cross Hospital   (Japan)

^f Celltrion Inc   (South Korea)

^g NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Biosimilar; CT P13; Infliximab; PK equivalence; Rheumatoid arthritis

Indexed keywords

BETA GLUCAN; BIOSIMILAR AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CT P13; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FOLIC ACID; GAMMA INTERFERON; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; BIOEQUIVALENCE; BRONCHITIS; CHEMILUMINESCENCE IMMUNOASSAY; CHLAMYDIAL PNEUMONIA; CLINICAL DISEASE ACTIVITY INDEX; CYSTITIS; DAS28; DEHYDRATION; DENTAL CARIES; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ELECTROCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; INFLUENZA; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; INTESTINE ULCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHARMACOKINETIC PARAMETERS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SINUSITIS; SPONTANEOUS ABORTION; TONSILLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX DYSPLASIA; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; JAPAN; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLIXIMAB; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84947032856     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1022297     Document Type: Article

References (17)

1. World Health Organization. Expert committee on biological standardization. Geneva, 2009 October 19-23. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf.
2. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, et al. Physicochemical characterization of Remsima®. MAbs. 2014;6(5):1163-77.
3. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12.
4. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-35.
7. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564-70.
8. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
9. van Riel PL, van Gestel AM, van de Putte LBA. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996;35(suppl. 2):4-7.
10. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-57.
11. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
12. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-45.
13. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429-35.
14. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1451-9.
15. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478-87.
16. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932-9.
17. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204769.